Xtl Biopharmaceuticals (XTLB) Notes Payables (2024 - 2025)
Xtl Biopharmaceuticals (XTLB) posted quarterly Notes Payables of $138000.0 for Q4 2025, little changed year-on-year from $138000.0 in Q4 2024, and up 60.47% on a QoQ basis from $86000.0 in Q2 2025.
Xtl Biopharmaceuticals (XTLB) Notes Payables (2024 - 2025) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Notes Payables for 2 consecutive years, with $138000.0 the latest figure, recorded in Q4 2025.
- Quarterly Notes Payables changed 0.0% year-over-year to $138000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $138000.0 (changed 0.0% YoY) and the FY2025 annual result came in at $138000.0, changed 0.0% from the prior year.
- Notes Payables advanced to $138000.0 in Q4 2025 per XTLB's latest filing, from $86000.0 in the prior quarter.
- Over the last five years, Notes Payables for XTLB reached as high as $168000.0 in Q3 2024 and fell as low as $86000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Xtl Biopharmaceuticals | 2.60 Bn | 2.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 138,000.00 |
| Jun 30, 2025 | 86,000.00 |
| Dec 31, 2024 | 138,000.00 |
| Sep 30, 2024 | 168,000.00 |